Reaktionsgleichung
[Br:1][C:2]1[CH:7]=[C:6]([F:8])[CH:5]=[CH:4][C:3]=1[CH:9]1[C:14]([C:15]([O:17][CH2:18][CH3:19])=[O:16])=[C:13]([CH2:20]Br)[NH:12][C:11]([C:22]2[S:23][C:24]([CH3:27])=[N:25][N:26]=2)=[N:10]1.[NH:28]1[CH2:33][CH2:32][O:31][CH2:30][CH:29]1[C:34]([OH:36])=[O:35]>>[Br:1][C:2]1[CH:7]=[C:6]([F:8])[CH:5]=[CH:4][C:3]=1[CH:9]1[N:10]=[C:11]([C:22]2[S:23][C:24]([CH3:27])=[N:25][N:26]=2)[NH:12][C:13]([CH2:20][N:28]2[CH2:33][CH2:32][O:31][CH2:30][CH:29]2[C:34]([OH:36])=[O:35])=[C:14]1[C:15]([O:17][CH2:18][CH3:19])=[O:16]Komponenten
3
Versuchsvorschrift
Ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(5-methyl-1,3,4-thiadiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (1.04 g, 2 mmol) was reacted with morpholine-3-carboxylic acid (0.26 g, 2 mmol) according to the procedure as described in Example 1, Step C to give the title compound as a yellow solid (0.63 g, 55%). The compound was characterized by the following spectroscopic data:
Quellen und Nachweise
- ORD-Eintrag
- ord-310ac3fada0b4997b134bb48ecfdac30
- Quelldatensatz
- uspto-grants-2016_05
- Patentnummer
- US09340538B2
Verknüpfte Notizen
Wird geladen…